Aethlon Medical, Inc.

  • Home
  • The Hemopurifier®
    • The Hemopurifier® in Infectious Disease
    • The Hemopurifier® in Cancer
    • Resources
  • About
    • Overview
    • Executive Team
    • Board of Directors
    • Contact Us
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Outside Media
    • Training Videos
  • Investors
    • Overview
    • Corporate News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • IRS Form 8937
News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Outside Media
  • Training Videos

Press Releases

Jun 22, 2020

Aethlon Medical Presents Hemopurifier® Data at the American Association for Cancer Research 2020 Annual Meeting

Jun 18, 2020

Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients

Jun 16, 2020

Aethlon Medical To Release Fourth Quarter Financial Results and Host Conference Call on June 25, 2020

Mar 24, 2020

Aethlon Announces Issuance of European Patent for the Hemopurifier® in Cancer

Feb 24, 2020

Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical Stock Expires

Feb 10, 2020

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Feb 10, 2020

Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical (NASDAQ:AEMD) Stock

Feb 6, 2020

Aethlon Medical To Release Third Quarter Financial Results and Host Conference Call on February 10, 2020

Jan 22, 2020

Aethlon Medical Announces Completion of $3.77 Million Registered Direct Offering

Jan 17, 2020

Aethlon Medical Announces $3.77 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...21
    • Twitter
    • Linkedin
    • YouTube
    Privacy Policy Disclaimer Sitemap
    © 2023 Aethlon Medical, Inc. All Rights Reserved.